Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial
Authors:
Open Access
- 30 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 75 (9) , 2376-2380
Abstract
Around the world, several dose regimens of hydroxychloroquine have been used for COVID-19 infection treatment, with the objective of identifying a short-term course. Hydroxychloroquine was found to decrease the viral replication in a concentration-dependent manner in vitro and to be more active when added prior to the viral challenge. A loading dose is used to rapidly attain a target drug concentration, which is usually considered as approximately the steady-state concentration. With a loading dose, the minimum effective concentration is reached much more rapidly than when using only the maintenance dose from the start. Thus, we propose a hydroxychloroquine sulphate dose regimen of 400 mg twice daily at Day 1 then 400 mg once daily from Day 2 to Day 10. We aim to evaluate this in the C-20-15 DisCoVeRy trial.Keywords
Funding Information
- Institut National de la Santé et de la Recherche Médicale (NCT04315948)
- Inserm
This publication has 12 references indexed in Scilit:
- COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progressionJournal of Antimicrobial Chemotherapy, 2020
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitroCell Discovery, 2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- Inhibition of autophagy protects against sepsis by concurrently attenuating the cytokine storm and vascular leakageJournal of Infection, 2019
- Pharmacogenetics of disease-modifying anti-rheumatic drugsBest Practice & Research Clinical Rheumatology, 2004
- Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemateChirality, 1994
- Bioavailability of hydroxychloroquine tablets in healthy volunteers.British Journal of Clinical Pharmacology, 1989
- The potential role of lysosomes in tissue distribution of weak basesBiopharmaceutics & Drug Disposition, 1988
- A dose‐ranging study of the pharmacokinetics of hydroxy‐chloroquine following intravenous administration to healthy volunteers.British Journal of Clinical Pharmacology, 1988
- Animal toxicity and pharmacokinetics of hydroxychloroquine sulfateThe American Journal of Medicine, 1983